SCHEMBL6035212

SCHEMBL6035212

Cn1cc(CC(=O)O)c(OCc2ccccc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.46
PKM P14618 1/20 0.43
PTGER1 P34995 2/20 0.42
PTGER4 P35408 1/20 0.42
PTGER3 P43115 1/20 0.42
PTGER2 P43116 1/20 0.42
ADORA3 P0DMS8 2/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
ALKBH1 Q13686 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
AKR1B1 P15121 1/20 0.40
JMJD6 Q6NYC1 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
BRD4 O60885 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5397261 0.88 ALDH1A1 (0.41) PTGDR2PKMPTGER1ADORA3ALDH1A1
SCHEMBL5405502 0.84 CNR1 (0.44) PKMPTGER1ADORA3ALDH1A1LMNA
SCHEMBL6036159 0.84 SMN1; SMN2 (0.43) PTGDR2PKMPTGER1PTGER4PTGER3
SCHEMBL5406901 0.82 KDM4E (0.57) PTGDR2PTGER1PTGER4PTGER3PTGER2
SCHEMBL5120593 0.82 PTGDR2 (0.46) PTGDR2PTGER1PTGER4PTGER3PTGER2
SCHEMBL4703265 0.81 ALKBH1 (0.51) PKMPTGER1ADORA3ALDH1A1LMNA
SCHEMBL5395193 0.78 FFAR1 (0.61)
SCHEMBL5401933 0.78 ATP4A (0.45) PKMADORA3MAPK1L3MBTL1ADORA2A
SCHEMBL6218172 0.77 PTPN1 (0.50) PKMPTGER1ADORA3ALDH1A1LMNA
SCHEMBL5395507 0.77 PPARG (0.63)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 PTGDR2 4688/4885PKM 2082/4885PTGER1 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.